A trial to analyze the impact of the anti-T-cell agents basiliximab and antithymocyte globulins (ATG) on antibody and cell-mediated immune responses after influenza vaccination in solid-organ transplant recipients.
Latest Information Update: 28 Jun 2016
At a glance
- Drugs Antithymocyte globulin (Primary) ; Basiliximab (Primary)
- Indications Transplant rejection
- Focus Therapeutic Use
- 28 Jun 2016 New trial record
- 12 May 2016 Results published in the Vaccine